Blog Single

Halifax, Nova Scotia — (Newsfile Corp. – March 25, 2024) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the “Study”).  An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy (“THT”) treatment shrunk within the first 24 hours, with an average reduction in size of 80% compared to matched controls.   

Study Principal Investigator, Dr. Carman Giacomantonio, comments, “Our initial assessment documented that in cohorts of seven animals, 7/7 of treated triple negative breast cancer mouse tumors bearing gold nanorods responded with an average reduction in tumor volume of 80% following a single treatment with near infrared light in comparison with untreated ‘control’ tumors.   Interestingly, in all cases we observed responses (tumor shrinkage) in distant, untreated tumors supporting the hypothesis that our observations are consistent with systemic immunogenic responses. This observation will be a significant focus of our research going forward. While we are encouraged by these initial results, there is still significant work to be completed.  The studies are designed to enable and identify statistical significance which will be achieved with the completion of the full Study.”